Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $4.50 Average Target Price from Analysts

Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) have been assigned an average recommendation of “Moderate Buy” from the five ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $4.50.

A number of research analysts have recently issued reports on the stock. Canaccord Genuity Group dropped their price target on shares of Tenaya Therapeutics from $6.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. Chardan Capital dropped their target price on Tenaya Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, December 12th. Morgan Stanley set a $2.00 price target on Tenaya Therapeutics in a report on Thursday, January 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Tenaya Therapeutics in a research note on Wednesday, January 21st. Finally, HC Wainwright cut their price objective on Tenaya Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, December 12th.

Tenaya Therapeutics Price Performance

Shares of NASDAQ TNYA opened at $0.79 on Friday. The stock has a fifty day moving average price of $0.91 and a 200 day moving average price of $1.15. Tenaya Therapeutics has a 1-year low of $0.36 and a 1-year high of $2.35. The company has a market cap of $131.54 million, a PE ratio of -1.01 and a beta of 3.18.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.03. Analysts anticipate that Tenaya Therapeutics will post -1.35 earnings per share for the current fiscal year.

Institutional Trading of Tenaya Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Scientech Research LLC acquired a new position in Tenaya Therapeutics during the third quarter worth about $27,000. Mirador Capital Partners LP boosted its stake in shares of Tenaya Therapeutics by 38.2% during the 3rd quarter. Mirador Capital Partners LP now owns 23,500 shares of the company’s stock worth $38,000 after acquiring an additional 6,500 shares in the last quarter. Comerica Bank acquired a new stake in shares of Tenaya Therapeutics in the 1st quarter worth approximately $50,000. Savant Capital LLC purchased a new position in Tenaya Therapeutics in the 2nd quarter valued at approximately $52,000. Finally, CWM LLC increased its stake in Tenaya Therapeutics by 25.2% in the 2nd quarter. CWM LLC now owns 90,087 shares of the company’s stock valued at $55,000 after purchasing an additional 18,142 shares in the last quarter. Hedge funds and other institutional investors own 90.54% of the company’s stock.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.